ALK-positive anaplastic large-cell lymphoma in adults: an individual patient data pooled analysis of 263 patients.
作者信息
Sibon David, Nguyen Dinh-Phong, Schmitz Norbert, Suzuki Ritsuro, Feldman Andrew L, Gressin Rémy, Lamant Laurence, Weisenburger Dennis D, Rosenwald Andreas, Nakamura Shigeo, Ziepert Marita, Maurer Matthew J, Bast Martin, Armitage James O, Vose Julie M, Tilly Hervé, Jais Jean-Philippe, Savage Kerry J
机构信息
Hematology Department, Necker University Hospital, Greater Paris University Hospitals, Paris Descartes University - Sorbonne Paris Cité, Paris, France
Biostatistics Department, Imagine Institute, Paris, France.
出版信息
Haematologica. 2019 Dec;104(12):e562-e565. doi: 10.3324/haematol.2018.213512. Epub 2019 Apr 19.
Abstract
摘要
相似文献
1
ALK-positive anaplastic large-cell lymphoma in adults: an individual patient data pooled analysis of 263 patients.成人ALK阳性间变性大细胞淋巴瘤：263例患者的个体患者数据汇总分析
Haematologica. 2019 Dec;104(12):e562-e565. doi: 10.3324/haematol.2018.213512. Epub 2019 Apr 19.
2
Phase II trial of dose-adjusted EPOCH in untreated systemic anaplastic large cell lymphoma.剂量调整的EPOCH方案治疗初治系统性间变性大细胞淋巴瘤的II期试验。
Haematologica. 2016 Jan;101(1):e27-9. doi: 10.3324/haematol.2015.131151. Epub 2015 Oct 30.
3
Combined Modality Management of Sinonasal Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma in a Young Adult-Report of a Rare Case.鼻腔鼻窦间变淋巴瘤激酶阳性间变大细胞淋巴瘤的联合治疗-一例罕见病例报告。
J Adolesc Young Adult Oncol. 2019 Aug;8(4):469-476. doi: 10.1089/jayao.2018.0158. Epub 2019 Apr 17.
4
Safety and effective salvage regimen comprising a novel combination of brentuximab vedotin, L-asparaginase, and dexamethasone for refractory anaplastic large cell lymphoma, anaplastic lymphoma kinase negative.用于难治性间变性大细胞淋巴瘤（间变性淋巴瘤激酶阴性）的安全有效的挽救方案，该方案包含本妥昔单抗、L-天冬酰胺酶和地塞米松的新型组合。
Hematol Oncol. 2019 Apr;37(2):212-214. doi: 10.1002/hon.2565. Epub 2018 Nov 19.
5
[Clinical features and prognosis for anaplastic large cell lymphoma].[间变性大细胞淋巴瘤的临床特征与预后]
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2018 Jun 28;43(6):631-637. doi: 10.11817/j.issn.1672-7347.2018.06.009.
6
The addition of etoposide to CHOP is associated with improved outcome in ALK+ adult anaplastic large cell lymphoma: A Nordic Lymphoma Group study.在CHOP方案中加入依托泊苷可改善ALK阳性成人间变性大细胞淋巴瘤的预后：一项北欧淋巴瘤研究组的研究。
Br J Haematol. 2017 Sep;178(5):739-746. doi: 10.1111/bjh.14740. Epub 2017 May 8.
7
"Double hit" anaplastic large cell lymphoma with concurrent ALK and MYC rearrangements.具有ALK和MYC同时重排的“双打击”间变性大细胞淋巴瘤。
Am J Hematol. 2020 Dec;95(12):1625-1627. doi: 10.1002/ajh.25980. Epub 2020 Sep 12.
8
Revealing the true face behind the mask of ALK-positive anaplastic large cell lymphoma (ALCL).揭开ALK阳性间变性大细胞淋巴瘤（ALCL）面具背后的真面目。
Ann Hematol. 2021 Apr;100(4):1107-1109. doi: 10.1007/s00277-020-04247-4. Epub 2020 Sep 8.
9
Secondary CNS involvement of ALK-negative anaplastic large cell lymphoma.ALK阴性间变性大细胞淋巴瘤的中枢神经系统继发性受累
Am J Hematol. 2017 Nov;92(11):1267-1268. doi: 10.1002/ajh.24733. Epub 2017 Jun 5.
10
"Double-hit" of DUSP22 and TP63 rearrangements in anaplastic large cell lymphoma, ALK-negative.间变性大细胞淋巴瘤（ALK阴性）中DUSP22和TP63重排的“双重打击”
Blood. 2020 Feb 27;135(9):700. doi: 10.1182/blood.2019004164.
引用本文的文献
1
Real-world data on long-term outcomes in patients with T-cell lymphomas: a nationwide study of Korea.T细胞淋巴瘤患者长期预后的真实世界数据：韩国的一项全国性研究。
Blood Res. 2025 Aug 21;60(1):47. doi: 10.1007/s44313-025-00095-1.
2
Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up.本妥昔单抗联合化疗一线治疗系统性间变性大细胞淋巴瘤：ECHELON-2研究5年随访的亚组分析
Blood Cancer J. 2025 Aug 1;15(1):129. doi: 10.1038/s41408-025-01329-2.
3
Comprehensive study of anaplastic large cell lymphoma: clinicopathological features from Indonesia.间变性大细胞淋巴瘤的综合研究：来自印度尼西亚的临床病理特征
BMC Res Notes. 2025 Jul 9;18(1):282. doi: 10.1186/s13104-025-07354-5.
4
Molecular Insights into the Diagnosis of Anaplastic Large Cell Lymphoma: Beyond Morphology and Immunophenotype.间变性大细胞淋巴瘤诊断的分子见解：超越形态学和免疫表型
Int J Mol Sci. 2025 Jun 19;26(12):5871. doi: 10.3390/ijms26125871.
5
Peripheral T- and natural killer-cell lymphomas: ESMO-EHA Clinical Practice Guideline for diagnosis, treatment, and follow-up.外周T细胞和自然杀伤细胞淋巴瘤：ESMO-EHA诊断、治疗及随访临床实践指南
Hemasphere. 2025 May 7;9(5):e70128. doi: 10.1002/hem3.70128. eCollection 2025 May.
6
[Not Available].[无可用内容]
Glob Reg Health Technol Assess. 2025 Apr 30;12:106-117. doi: 10.33393/grhta.2025.3306. eCollection 2025 Jan-Dec.
7
TP53 deletion is associated with poor survival of adult ALK-positive ALCL patients receiving CHOP-based chemotherapy.TP53缺失与接受基于CHOP化疗的成年ALK阳性间变性大细胞淋巴瘤（ALCL）患者的不良生存相关。
Ann Hematol. 2025 Mar;104(3):1801-1806. doi: 10.1007/s00277-025-06297-y. Epub 2025 Mar 10.
8
ALK + anaplastic large cell lymphoma involving the bladder: case report and review of the literature.ALK阳性间变性大细胞淋巴瘤累及膀胱：病例报告及文献复习
Diagn Pathol. 2024 Dec 18;19(1):157. doi: 10.1186/s13000-024-01585-z.
9
Advances in peripheral T cell lymphomas: pathogenesis, genetic landscapes and emerging therapeutic targets.外周T细胞淋巴瘤的进展：发病机制、基因图谱及新兴治疗靶点
Histopathology. 2025 Jan;86(1):119-133. doi: 10.1111/his.15376.
10
Fifteen Years of Non-Hodgkin Lymphoma in an Indonesian National Referral Hospital: Epidemiologic Trends and Diagnostic Challenges.印度尼西亚国家转诊医院 15 年非霍奇金淋巴瘤：流行病学趋势和诊断挑战。
JCO Glob Oncol. 2024 Oct;10:e2400346. doi: 10.1200/GO-24-00346. Epub 2024 Nov 7.
本文引用的文献
1
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.贝林妥欧单抗联合化疗治疗 CD30 阳性外周 T 细胞淋巴瘤（ECHELON-2）：一项全球性、双盲、随机、3 期临床试验。
Lancet. 2019 Jan 19;393(10168):229-240. doi: 10.1016/S0140-6736(18)32984-2. Epub 2018 Dec 4.
2
Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study.克唑替尼在ALK阳性肿瘤（非小细胞肺癌除外）中的长期疗效：一项1b期开放标签研究。
Am J Hematol. 2018 May;93(5):607-614. doi: 10.1002/ajh.25043. Epub 2018 Feb 8.
3
Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma.本妥昔单抗治疗复发或难治性系统性间变性大细胞淋巴瘤患者的5年结果
Blood. 2017 Dec 21;130(25):2709-2717. doi: 10.1182/blood-2017-05-780049. Epub 2017 Oct 3.
4
The addition of etoposide to CHOP is associated with improved outcome in ALK+ adult anaplastic large cell lymphoma: A Nordic Lymphoma Group study.在CHOP方案中加入依托泊苷可改善ALK阳性成人间变性大细胞淋巴瘤的预后：一项北欧淋巴瘤研究组的研究。
Br J Haematol. 2017 Sep;178(5):739-746. doi: 10.1111/bjh.14740. Epub 2017 May 8.
5
Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network.专家组对淋巴瘤诊断的影响：法国淋巴病理网络的患者研究。
J Clin Oncol. 2017 Jun 20;35(18):2008-2017. doi: 10.1200/JCO.2016.71.2083. Epub 2017 May 1.
6
The biology and management of systemic anaplastic large cell lymphoma.系统性间变性大细胞淋巴瘤的生物学特性与治疗策略。
Blood. 2015 Jul 2;126(1):17-25. doi: 10.1182/blood-2014-10-567461. Epub 2015 Apr 13.
7
Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry.真实世界外周 T 细胞淋巴瘤的预后因素和治疗数据：来自瑞典淋巴瘤登记处的一项研究。
Blood. 2014 Sep 4;124(10):1570-7. doi: 10.1182/blood-2014-04-573089. Epub 2014 Jul 8.
8
ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes.ALK阴性间变性大细胞淋巴瘤是一种基因异质性疾病，临床结局差异很大。
Blood. 2014 Aug 28;124(9):1473-80. doi: 10.1182/blood-2014-04-571091. Epub 2014 Jun 3.
9
Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte trials.成人系统性间变性大细胞淋巴瘤在 Groupe d'Etude des Lymphomes de l'Adulte 试验中的长期疗效。
J Clin Oncol. 2012 Nov 10;30(32):3939-46. doi: 10.1200/JCO.2012.42.2345. Epub 2012 Oct 8.
10
Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95. upfront VIP-reinforced-ABVD（VIP-rABVD）方案并不优于 CHOP/21 方案用于治疗新诊断的外周 T 细胞淋巴瘤。GOELAMS-LTP95 随机 III 期试验的结果。
Br J Haematol. 2010 Oct;151(2):159-66. doi: 10.1111/j.1365-2141.2010.08329.x. Epub 2010 Aug 25.
Zotero 插件